VCYTHealthcare · Diagnostics & ResearchThe 12 Wall Street analysts covering Veracyte, Inc. hold a median 12-month price target of $63 — +20.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Veracyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Volatility (56): The share price moves around a lot.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VCYT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +20.0% from it.
Of the 20 most recent actions, 5 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Sept 2026 | Freedom Capital Markets | Maintains | Buy | $66 |
| 9 Sept 2026 | UBS | Maintains | Buy | $52 → $65 |
| 4 Aug 2026 | Morgan Stanley | Maintains | Underweight | — |
| 4 Aug 2026 | Morgan Stanley | Maintains | Underweight | $47 → $44 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | $66 → $54 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 4 Aug 2026 | Stephens & Co. | Maintains | Overweight | $68 → $55 |
| 4 Aug 2026 | Stephens & Co. | Maintains | Overweight | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Hold | $60 → $50 |
| 31 July 2026 | Needham | Maintains | Buy | — |
| 31 July 2026 | Needham | Maintains | Buy | $57 → $69 |
| 30 July 2026 | Needham | Maintains | Buy | $57 → $69 |
| 30 July 2026 | Needham | Maintains | Buy | — |
| 15 July 2026 | Piper Sandler | Initiates | Overweight | $66 |
| 15 July 2026 | Piper Sandler | Initiates | Overweight | — |
| 14 July 2026 | Canaccord Genuity | Maintains | Hold | $42 → $60 |
| 14 July 2026 | Canaccord Genuity | Maintains | Hold | — |
| 9 July 2026 | Morgan Stanley | Maintains | Underweight | $37 → $47 |
| 9 July 2026 | Morgan Stanley | Maintains | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VCYT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Veracyte, Inc. returned +45.4% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 17% of US stocks
Cheaper than 31% of US stocks
Cheaper than 8% of US stocks
Higher than 63% of US stocks
Higher than 54% of US stocks
Higher than 85% of US stocks
Higher than 73% of US stocks
Higher than 82% of US stocks
Higher than 60% of US stocks
Higher than 71% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Veracyte, Inc. has a market value of $3.9B and an enterprise value of $3.5B.
Revenue in the twelve months to 30 June 2026: $561.9M. The latest quarter grew 15.5% year on year.
Net income over the same four quarters: $114.5M, a 20.4% net margin.
Diluted earnings per share, trailing twelve months: $1.41.
Free cash flow in the twelve months to 30 June 2026: $166.0M.
Trailing P/E: 35.8×; forward P/E: 25.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Veracyte, Inc. employs 755 people — $744K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Veracyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Veracyte reported third-quarter 2026 revenue of $151.8 million, including $146.4 million in testing revenue, which grew 15% year over year. The company also announced a $100 million share repurchase program.
Why it matters — The results provide updates on Veracyte’s revenue growth and capital-return plans.
Ten Afirma abstracts will be presented at ATA 2026, including two oral presentations and eight posters. The presentations focus on thyroid nodule diagnosis and cancer research.
Why it matters — Afirma is featured in research presentations relevant to thyroid nodule diagnosis and cancer, areas of interest to Veracyte watchers.
Veracyte announced it will participate in the UBS Global Healthcare Conference in Palm Beach Gardens, Florida. A fireside chat is scheduled for Tuesday, November 10 at 4:15 p.m.
Why it matters — The announcement provides VCYT watchers with details about the company's upcoming investor-conference appearance.
Zacks Investment Research says Veracyte has two key ingredients associated with a likely earnings beat in its upcoming report. The item highlights expectations ahead of the report.
Why it matters — VCYT watchers may find the stated earnings-beat outlook relevant as they follow the company’s upcoming report.
Artisan Mid Cap Fund reported a negative absolute return for Q3 2026 while outperforming the Russell Midcap Growth Index. It added Manhattan Associates, Okta and Clean Harbors, and exited Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals.
Why it matters — The excerpt does not mention Veracyte or disclose any change to the fund’s position in VCYT, so its relevance to a VCYT watcher is limited.
The 12 Wall Street analysts covering Veracyte, Inc. have a median 12-month price target of $63, with estimates ranging from $45 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Veracyte, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veracyte, Inc. 93 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Veracyte, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +20.0% from the last close, and Ticker Nerd's factor model ranks Veracyte, Inc. 93 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Veracyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCYT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $70 over the next 12 months.
Veracyte, Inc. returned +45.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Veracyte Announces Third Quarter 2026 Financial Results". Veracyte reported third-quarter 2026 revenue of $151.8 million, including $146.4 million in testing revenue, which grew 15% year over year. The company also announced a $100 million share repurchase program.
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases. Veracyte’s current portfolio includes laboratory-developed tests for thyroid, prostate, bladder, and breast cancer, as well as tests for lung disease and lung cancer-related decision support. The company also provides products and services such as Afirma, Decipher, Percepta, Envisia, Prosigna, Immunoscore, and nCounter analysis capabilities, supporting diagnosis, prognosis, and treatment selection across multiple care settings. Its work is centered on using genomic and clinical data to reduce diagnostic uncertainty and improve decision-making for physicians, pathologists, and patients. Headquartered in South San Francisco, California, Veracyte operates as a global diagnostics business with a focus on molecular testing, evidence generation, and clinical utility in oncology and related specialties.
CEO Mr. Marc A. Stapley · 755 employees · United States · https://www.veracyte.com
